Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear receptor-interacting protein 2 (NRIP2)
- Target
- NRIP2
- Molecular classification
- Protein, Transcriptional regulator, Nuclear receptor co-regulator, Proteolysis-associated protein
01
Overview
Nuclear receptor-interacting protein 2 is a multifunctional protein that acts as a transcriptional co-regulator, binding nuclear receptors such as retinoic acid and thyroid hormone receptors in a ligand-dependent manner. It is now recognized as a key stabilizer of β-catenin in the Wnt signaling pathway, with important roles in podocyte injury and colorectal cancer-initiating cell renewal. NRIP2 operates principally in the cytoplasm and nucleus, influencing signal transduction, cellular proteolysis, and transcription repression. Dysregulation of NRIP2 has been implicated in kidney pathology, certain cancers, and rare genetic syndromes.
- Other names
- DKFZP761G1913NIX1NRIP2nuclear receptor-interacting protein 2
02
Mechanism of action
Stabilizes β-catenin by preventing its ubiquitin-mediated proteasomal degradation. Regulates transcription by interacting with nuclear receptors, including retinoic acid receptor (RAR) and thyroid hormone receptor (THR), in a ligand-dependent manner.
03
Biological functions
Transcriptional regulation (down-regulates activity of certain nuclear receptors, such as NR1F2)Interaction and stabilization of β-catenin, affecting Wnt/β-catenin pathway activityProteolysisModulation of Notch signaling
04
Disease associations
Cancer (upregulated in colorectal cancer-initiating cells)Podocyte injury and proteinuria in kidney disease, notably focal segmental glomerulosclerosis (FSGS)Sneddon syndromeTemtamy syndrome
05
Safety considerations
Overexpression may promote pathological β-catenin activation, contributing to podocyte injury and proteinuriaTherapeutic targeting could affect essential transcriptional regulation pathways, with unknown systemic effects
06
Biomarkers
NRIP2 expression (notably in podocytes for kidney disease)β-catenin activation status (for disease activity and progression in relevant contexts)
Beyond the preview
Go deeper on Nuclear receptor-interacting protein 2 (NRIP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear receptor-interacting protein 2 (NRIP2).